

Four Seasons Health Care

2017 Investor Presentation
Preliminary, unaudited results for the year ended 31 December 2017

27 April 2018

Disclaimer

THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES IN THE UNITED STATES OF AMERICA OR IN ANY OTHER JURISDICTION. IT IS PROVIDED AS INFORMATION ONLY.

This presentation is furnished only for the use of the intended recipient and may not be relied upon for the purposes of entering into any transaction. By attending, viewing, reading or otherwise accessing this presentation, you are agreeing to be bound by these restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

Certain information herein (including market data and statistical information) has been obtained from various sources. No representation, warranty or undertaking (whether express or implied) is made by Elli Investments Limited or its direct or indirect subsidiaries (together, the "Group" or "we") as to the completeness, accuracy or fairness of the information contained in this presentation or that this presentation is suitable for the recipient's purposes. All projections, valuations and statistical analyses are provided to assist the recipient in the evaluation of the matters described herein. They may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results and to the extent that they are based on historical information, they should not be relied upon as an accurate prediction of future performance.

This presentation contains a brief overview solely of the matters to which it relates and does not purport to provide an exhaustive summary of all relevant issues, nor does it constitute a "Prospectus" or an "advertisement" for the purposes of Directive 2003/71/EC.

This presentation contains various forward-looking statements that reflect management's current views with respect to future events and anticipated financial and operational performance. Forward-looking statements as a general matter are all statements other than statements as to historical facts or present facts or circumstances. Such statements are made on the basis of assumptions and expectations that we currently believe are reasonable but could prove to be wrong. The words "believe", "expect", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions, identify certain of these forward-looking statements. Other forward-looking statements can be identified in the context in which the statements are made. Forward-looking statements include, among other things, statements relating to our strategy, outlook and growth prospects, our operational and financial targets, our liquidity, capital resources and capital expenditure, our planned investments, the expectations as to future growth in demand for our services, general economic trends and trends in the healthcare industry, the impact of regulations on us and our operations and the competitive environment in which we operate. Although we believe that the expectations reflected in these forward-looking statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements. Forward-looking statements speak only as of the date of this presentation.

We expressly undertake no obligation to publicly update or revise any of the information, forward-looking statements or any conclusions contained herein, whether as a result of new information, future events or otherwise, other than as required by law or regulation. Accordingly, investors are cautioned not to place undue reliance on any of the forward-looking statements herein.

This presentation does not constitute an offer or an agreement, or a solicitation of an offer or an agreement, to enter into any transaction (including for the provision of any services) and does not constitute an offer or invitation to subscribe for or purchase any securities, and nothing contained herein shall form the basis of any contract or commitment whatsoever. Any decision to purchase securities in the context of a proposed offering, if any, should be made solely on the basis of information contained in the offering memorandum published in relation to such an offering.

The information contained herein does not constitute financial product, investment, legal, accounting, regulatory, taxation or other advice, a recommendation to invest in the securities of any Group company or any other person, or an invitation or an inducement to engage in investment activity with any person, and the information does not take into account your investment objectives or legal, accounting, regulatory, taxation or financial situation or particular needs, and consequently the information contained herein may not be sufficient or appropriate for the purpose for which a recipient might use it. You are solely responsible for forming your own opinions and conclusions on such matters and the market and for making your own independent assessment of the information herein. You are solely responsible for seeking independent professional advice in relation to the information and any action taken on the basis of the information. Investors and prospective investors in the securities of any issuer mentioned herein are required to make their own independent investigation and appraisal of the business and financial condition of such issuer and the nature of the securities.

This presentation includes certain financial data that are "non-GAAP financial measures". These non-GAAP financial measures do not have a standardised meaning prescribed by International Financial Reporting Standards or UK Accounting Standards and therefore may not be comparable to similarly titled measures presented by other entities, nor should they be construed as an alternative to other financial measures determined in accordance with International Financial Reporting Standards or UK Accounting Standards. Although we believe these non-GAAP financial measures provide useful information to users in measuring the financial performance and condition of the business, you are cautioned not to place undue reliance on any non-GAAP financial measures included in this presentation. This presentation contains certain data and forward-looking statements regarding the U.K. economy, the markets in which we operate and its position in the industry that were obtained from publicly available information, independent industry publications and other third-party data. We have not independently verified such data and forward-looking statements and cannot guarantee their accuracy or completeness.

This presentation has not been reviewed or approved by any rating agency, note trustee, the Irish Stock Exchange or any other person. To the fullest extent permitted by law, each Group company, and the directors, officers, employees, agents, partners, affiliates, managers and professional (including financial and legal) advisers of any Group company (together, the "Group Parties") will have no tortious, contractual or any other liability to any person in connection with the use of this presentation. The Group Parties accept no liability whatsoever to any person, regardless of the form of action, including for any lost profits or lost opportunity, or for any indirect, special, consequential, incidental or punitive damages arising from any use of this presentation, its contents or preparation or otherwise in connection with it, even if any Group Party has been advised of the possibility of such damages.



2017 Overview

Group financial highlights¹

- 2017 saw the group make progress in occupancy and average weekly fee despite the difficult environment in which it operates
- Full year 2017 turnover for Elli Investments Limited is £31.4m, or 5.3%, higher than 2016 after adjusting for the impact of disposals and closures (an average reduction of c2,700 effective beds) and the impact of an extra week in 2017
- 2017 EBITDA of £53.7m is £1.8m lower than 2016
- Average group occupancy % in 2017 saw a 1.4 percentage point increase over 2016 (Four Seasons Health Care: 1.7 percentage point increase; brighterkind: 0.5 percentage point decrease; The Huntercombe Group (THG): 1.2 percentage point increase)
- Average weekly fee in Four Seasons Health Care increased by 6.3% year on year with the full year impact of the 2016 NHS Funded Nursing Care, acuity increase, and the mix benefits of closures and disposals bolstering a lower underlying inflationary increase
- In brighterkind, the increased proportion of self-funded residents and the FNC impact contributed to the 8.9% year on year increase
- Improvements in quality, with over 71% of the group's care homes rated as Good or Outstanding, or the approximate equivalents under the different regulators, as at April 2018 an increase from around 64% as at April 2017
- Average 2017 payroll as a percentage of turnover in the group's care homes, at 63.7%, remained consistent with 2016 despite inflationary pressures
 and the continued shortage of nurses. Within THG, payroll as a percentage of turnover increased by 2.9 percentage points compared to the previous
 year
- Agency as a percentage of payroll of 8.9% in 2017 in the group's care homes represented a 1.7 percentage point increase compared to 2016 (Four Seasons Health Care: 2.2 percentage point increase; brighterkind: 0.7 percentage point improvement). Within THG, agency as a percentage of payroll increased by 3.4 percentage points in 2017 compared to the 2016 average
- In 2017 the group generated £26.0m of cash from operations
- Closing 2017 cash balance of £26.0m; net debt of £539.0m at December 2017 (excluding the unpaid December 2017 coupon of c£26m, amounts owed to related undertakings and debt issue costs)

Note 1: Preliminary, unaudited results for the year ended 31 December 2017



Results – KPIs

Turnous (Cm)	
Turnover (£m)	
EBITDAR (£m) ⁽⁶⁾	
EBITDA (£m)	
Effective beds - group	
Occupied beds - group	
Occupancy % - FSHC and brighterkind	
Occupancy % - THG	
Average weekly fee (£) - FSHC and brighterkind	
Average weekly fee (£) - THG	
Payroll (% of turnover) ⁽¹⁾ - FSHC and brighterkind	
Payroll (% of turnover) ⁽¹⁾ - THG	
EBITDARM (% of turnover) ⁽⁶⁾ - FSHC and brighterkind	
EBITDARM (% of turnover) (4)(6) - THG	
Agency (% of payroll) ⁽¹⁾	
Expenses (% of turnover)	
Central costs (% of turnover)	
Maintenance capex (£m) ⁽³⁾	

		2016		
Q1	Q2	Q3	Q4	Year ⁽²⁾
170.7	177.0	171.7	166.8	686.2
21.8	25.8	32.1	20.1	99.8
9.2	13.6	19.7	13.0	55.4
21,045	20,438	19,338	18,532	19,838
18,183	17,822	17,205	16,573	17,446
86.7%	87.5%	89.6%	90.0%	88.4%
81.7%	82.3%	79.1%	79.2%	80.6%
629	669	675	681	663
2,390	2,425	2,386	2,395	2,399
65.3%	63.6%	62.1%	64.0%	63.8%
71.2%	68.9%	72.9%	74.0%	71.8%
18.9%	22.2%	24.4%	21.0%	21.6%
18.6%	20.1%	16.4%	14.5%	17.4%
7.9%	6.9%	8.2%	9.0%	8.0%
14.9%	13.7%	13.1%	14.5%	14.1%
6.1%	5.9%	6.0%	6.1%	6.0%
6.5	6.8	6.1	7.9	27.3

		2017 ⁽⁷⁾		
Q1	Q2	Q3	Q4	Year ⁽²⁾
163.9	164.5	162.1	169.9	660.4
23.2	24.5	25.7	22.9	96.3
11.8	13.5	13.9	14.5	53.7
17,831	17,214	16,753	16,378	17,044
15,911	15,332	15,016	14,657	15,229
89.7%	89.4%	90.0%	89.9%	89.8%
81.4%	82.4%	82.3%	81.2%	81.8%
692	717	721	720	712
2,607	2,721	2,876	3,016	2,805
63.7%	63.7%	63.0%	64.4%	63.7%
72.9%	74.2%	76.3%	75.3%	74.7%
21.3%	22.3%	23.7%	21.1%	22.1%
16.3%	15.2%	12.6%	13.4%	14.4%
9.1%	9.7%	11.1%	10.3%	10.1%
14.5%	13.5%	13.1%	14.1%	13.8%
6.3%	6.3%	5.9%	6.4%	6.2%
4.9	5.5	7.0	11.6	29.0

Notes

- 1. Payroll (% of turnover) excludes central payroll
- 2. Full year numbers may include minor rounding differences compared to the four quarter aggregate
- 3. Four Seasons Health Care, brighterkind and THG operational capex
- 4. Includes £0.2m rental income per quarter
- 5. Q2 and Q3 2016 KPIs, other than EBITDA and EBITDAR, include the FNC fee rate increase, announced in July 2016 and backdated to 1 April 2016, in the relevant period
- 6. EBITDAR(M) = Pre-exceptional Earnings Before Interest, Tax, Depreciation, Amortisation, Rent (and Central costs)
- 7. 2017 is a 53 week period



Results – KPIs by business


ı	2016			2017 ⁽⁵⁾						
	Q1	Q2	2016 Q3	Q4	Year ⁽²⁾	Q1	Q2	2017 ⁽³⁾	Q4	Year ⁽²⁾
Turnover (£m)	~-			<u> </u>		~-	~-		<u> </u>	
- FSHC	119.9	124.6	120.8	116.5	481.9	113.2	112.3	110.1	115.1	450.6
- brighterkind	21.8	22.8	22.8	23.2	90.5	23.3	24.0	24.5	26.6	98.5
- THG										
	29.0	29.5	28.0	27.2	113.7	27.3	28.1	27.5	28.2	111.2
Effective beds										
- FSHC	17,659	17,086	16,041	15,291	16,519	14,690	14,105	13,712	13,403	13,977
- brighterkind	2,298	2,264	2,209	2,209	2,245	2,208	2,208	2,208	2,208	2,208
- THG	1,088	1,088	1,088	1,032	1,074	934	901	833	766	859
Occupancy %										
- FSHC	86.6%	87.7%	89.8%	90.4%	88.6%	90.2%	90.0%	90.5%	90.3%	90.3%
- brighterkind	86.9%	86.0%	87.5%	87.4%	86.9%	85.8%	85.7%	86.8%	87.3%	86.4%
- THG	81.7%	82.3%	79.1%	79.2%	80.6%	81.4%	82.4%	82.3%	81.2%	81.8%
Average weekly fee (£)										
- FSHC	603	640	645	648	634	657	680	682	679	674
- brighterkind	831	891	899	917	885	937	968	973	976	964
- THG	2,390	2,425	2,386	2,395	2,399	2,607	2,721	2,876	3,016	2,805
Payroll % (of turnover) ⁽¹⁾										
- FSHC	66.3%	64.3%	63.0%	65.3%	64.7%	64.8%	64.9%	64.6%	66.3%	65.2%
- brighterkind	59.9%	60.1%	57.4%	57.7%	58.8%	58.2%	57.8%	55.9%	56.0%	57.0%
- THG	71.2%	68.9%	72.9%	74.0%	71.8%	72.9%	74.2%	76.3%	75.3%	74.7%
Agency % (of payroll) ⁽¹⁾										
- FSHC	6.9%	6.3%	8.2%	8.9%	7.6%	9.0%	9.6%	10.7%	9.9%	9.8%
- brighterkind	3.9%	5.7%	4.0%	6.0%	4.9%	5.3%	3.7%	4.3%	3.5%	4.2%
- THG	14.0%	10.2%	11.1%	11.2%	11.6%	12.3%	14.3%	17.1%	16.6%	15.0%
EBITDARM % (of turnover)										
- FSHC	17.7%	21.3%	23.4%	19.4%	20.5%	19.8%	20.7%	21.7%	18.6%	20.2%
- brighterkind	25.5%	27.0%	29.8%	28.8%	27.8%	28.3%	29.8%	32.3%	32.2%	30.6%
- THG	18.6%	20.1%	16.4%	14.5%	17.4%	16.3%	15.2%	12.6%	13.4%	14.4%

Notes

- 1. Payroll (% of turnover) excludes central payroll
- 2. Full year numbers may include minor rounding differences compared to the four quarter aggregate
- 3. Q1 Q4 2016 include £0.2m rental income per quarter
- 4. Q2 and Q3 2016 KPIs, other than EBITDA and EBITDAR, include the FNC fee rate increase, announced in July 2016 and backdated to 1 April 2016, in the relevant period
- 5. 2017 is a 53 week period



Regulatory Ratings




- The group's regulatory ratings have improved considerably over the past 12 months, as shown above, and remain ahead of the relevant market comparator
- The most recent appropriate comparators for the group's care homes are the CQC's classifications of 'medium' and 'large' nursing homes, which include all care homes with 11 beds or more
- Across all regions, the percentage of Four Seasons Health Care homes rated as 'Good' has increased over the past 12 months by more than 2.8 percentage points, with more than 70% of homes rated as 'Good' or 'Outstanding'
- More than 75% of the brighterkind High Yield Bond homes are rated as 'Good'
- THG has 80% of facilities rated as 'Good' which is higher than the national average for 'Good' or 'Outstanding' for all hospital inspections


Note: Scottish and Northern Irish homes are rated using different scales, which have been translated to the CQC equivalents and included in this chart




Results – Four Seasons Health Care



Average weekly fee (£)




Payroll % of turnover (rolling 3 months)




- Occupancy % remained consistent throughout 2017, benefitting from the closure of lower occupancy loss-making and unviable homes
- 2017 average occupancy of 90.3% was 1.7 percentage points above the average for 2016, with Q4 2017 occupancy of 90.3% being in line with the corresponding quarter in 2016
- Q1 2018 occupancy has suffered from a very high level of winter deaths, consistent with the c14% national increase for over 85s over the last four year average for the same period (ONS)
- Average weekly fee of £674 in 2017 was 6.3% higher than 2016, driven by the full year effect of the increase in FNC fee rate, the benefits of improved care quality, higher average acuity, and the benefit of homes disposals and closures
- Payroll as a % of turnover declined by 0.5 percentage points in 2017 compared to the prior year
- Agency as a percentage of payroll increased from 7.6% in 2016 to 9.8% in 2017, a 2.2 percentage point increase which reflects the ongoing difficulties in nurse and carer recruitment




Results – brighterkind



Average weekly fee (£)




Payroll % of turnover (rolling 3 months)



- 2017 average occupancy of 86.4% was 0.5 percentage points lower than 2016
- Q4 2017 occupancy was 0.5 percentage points higher than the prior quarter, continuing the growth in occupancy achieved in Q3 2017. Q1 2018 was similarly impacted by the high level of winter deaths
- Private mix increased over the course of the year, ending 2017 at almost 51%, partly driven by the rebranding of brighterkind homes
- As a result, the average weekly fee in 2017 was 8.9% higher than 2016
- Payroll as a % of turnover in 2017 improved by 1.8 percentage points in comparison to 2016
- Tight control of agency spend was maintained in 2017 with agency usage as a percentage of payroll at 4.2% in 2017, an improvement of 0.7 percentage points compared to 2016




Results – THG



Average weekly fee (£)



Payroll % of turnover (rolling 3 months)




- Occupancy percentage of 81.8% in 2017 was 1.2 percentage points higher than 2016, with occupancy in Q4 2017 being 2.0 percentage points higher than the comparable quarter in 2016
- Average weekly fee in 2017 was 16.9% higher than in 2016, largely reflecting the higher acuity mix following the repositioning of the THG estate though the disposal of a number of lower acuity sites during late 2016 and the first half of 2017 together with changing commissioning needs
- Payroll as a % of turnover was 2.9 percentage points higher in 2017 than 2016
- This was a function of the higher average acuity in the estate following the repositioning, the resolution of certain care issues in the estate and the closure of Norwich and Watcombe
- Agency usage, at 15.0% of total payroll in 2017, was 3.4 percentage points higher than in 2016 with similar drivers to the payroll % and remains a critical area of focus for the management team



Results – LTM September 2017 v LTM December 2017

Group EBITDA LTM Sep 2017 v LTM Dec 2017



- December 2017 LTM EBITDA was £53.7m, £2.5m up on September 2017 LTM after adjusting for the £2.4m impact of disposals and closures and the £1.4m impact of the additional week in Q4 2017
- The LTM movement, excluding closures and disposals, was largely a result of the following drivers:
 - Income was £5.7m higher in December 2017 LTM than September 2017 LTM:
 - Group fee rates were higher leading to an overall favourable fee rate variance of £7.6m
 - Lower occupancy in Q4 2017 resulting in an adverse occupancy variance of £1.9m
 - Own staff payroll costs increased by £2.9m, driven largely by an additional quarter of increased National Living Wage and National Minimum Wage
 - Agency spend in December 2017 LTM was £2.0m higher than the spend in September 2017 LTM, reflecting the continuing difficulties in the nurse and carer recruitment market particularly in FSHC and THG

Notes

1. Excludes closures/disposals



Results – Cash flow and net debt

External Debt						
£m	Debt Principal	Coupon/ Interest	Maturity			
High yield bonds						
Senior secured notes	350.0	8.75%	Jun 2019			
Senior notes	175.0	12.25%	Jun 2020			
Total HYB	525.0					
Term loan	40.0	L. +6% margin	Mar 2019			
Total amount outstanding on external debt	565.0					
<u>-</u>						
Cash at 31 December 2017	26.0					
Net debt (before debt issue costs)	539.0					

- At 31 December 2017 the group's cash balance was £26.0m
- The resulting net debt balance was £539.0m, excluding the unpaid December 2017 coupon of c£26.0m

Cash flow					
£m	Year ended Dec 2017	Year ended Dec 2016			
Net cash inflow from operating activities (1)	26.0	32.2			
Returns on investment and servicing of finance	(28.7)	(55.3)			
Acquisition of tangible fixed assets	(38.4)	(42.9)			
Proceeds from sale of tangible fixed assets	35.8	44.0			
Net cash outflow before financing	(5.3)	(22.1)			
Financing	(1.8)	-			
Decrease in cash in the period	(7.0)	(22.1)			
Opening cash balance	33.0	55.1			
Closing cash balance	26.0	33.0			
(1) Includes interest received and tax received of £2.9m(2016: £0.6m)					

- Capital expenditure in 2017 was £38.4m, whilst proceeds from the disposal of 33 homes totalled £35.8m
- The decrease in net cash inflow from operating activities in comparison to 2016 was a function of working capital timing and a decrease in EBITDA and additional exceptional spend
- Acquisition of tangible fixed assets includes £5.6m of development capital expenditure in the brighterkind business
- The group did not pay the c£26m of interest due in December 2017 in respect of the senior secured notes and senior notes



Developments and disposals

- Developments
 - A number of refurbishments across the group were completed during 2017
- Disposals
 - The group has taken the opportunity to dispose of, or close, certain care homes which are loss making, underperforming or non-core sites
 - In 2017 the group disposed of 32 freehold properties and one long leasehold, realising £35.8m in cash proceeds
 - The group continues to evaluate offers that have been received on other loss-making, underperforming or non-core sites



Q&A

- Questions can be addressed to:
 - Email: <u>investorinfo@fshc.co.uk</u>
 - Telephone: Ben Taberner +44 1625 417800
- An investor relations page is available on the FSHC website: www.fshc.co.uk

